Rocuronium is named as an intervention in 4 current clinical trials in our China, Denmark, Poland and Turkey registers. 2 are recruiting patients now. The most common phase is Not applicable. The sponsor with the most trials is Jiangsu HengRui Medicine Co., Ltd (1). The most-studied condition is Neuromuscular Blockade. The EU clinical trials register (CTIS) separately lists 1 authorised or ongoing trial.
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Authorised or ongoing trials in the EU Clinical Trials Information System that list a product containing Rocuronium. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.
| Study | Phase | Status | Sponsor | Countries |
|---|---|---|---|---|
|
Rapid sequence emergence of general Anaesthesia
2024-516415-24-03 · CTIS ↗ · Anesthesia and Analgesia
|
Phase 4 | Authorised | Stichting Radboud universitair medisch centrum | Netherlands |
The same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.
8 single-substance products containing Rocuronium on the HPRA medicines list.
| Lead sponsor | Trials |
|---|---|
| Jiangsu HengRui Medicine Co., Ltd | 1 |
| Nordsjaellands Hospital | 1 |
| 4th Military Clinical Hospital with Polyclinic, Poland | 1 |
| Ankara City Hospital Bilkent | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 1 | 0 |
| Clinical trials in Denmark | 1 | 1 |
| Clinical trials in Poland | 1 | 1 |
| Clinical trials in Turkey | 1 | 0 |
| EU register (CTIS) | 1 | — |
A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.
4 current trials in our China, Denmark, Poland and Turkey registers name Rocuronium as a drug or biological intervention, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Yes. 2 of the 4 trials are recruiting: 1 with sites in Denmark and 1 with sites in Poland. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Jiangsu HengRui Medicine Co., Ltd (1), Nordsjaellands Hospital (1), 4th Military Clinical Hospital with Polyclinic, Poland (1) and Ankara City Hospital Bilkent (1). The number in brackets is how many trials each organisation leads.
Yes. The HPRA medicines list includes 8 single-substance products containing Rocuronium, for example Rocuronium 10 mg/ml solution for injection/infusion (B. Braun Melsungen AG). A licence does not mean a product is currently marketed or reimbursed; see each product's record.
The registers we track list 1 entry for Rocuronium: US FDA: current. Shortages are product- and country-specific; check with a pharmacist.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Rocuronium works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Rocuronium works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Rocuronium (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 26 Sep 2026.